• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MT-141与拉氧头孢治疗复杂性尿路感染的快速细菌学反应比较。

Comparison of rapid bacteriological response to MT-141 and latamoxef in complicated urinary tract infections.

作者信息

Miyamoto S, Tamiya T, Takatsuka K, Kumamoto Y

出版信息

Drugs Exp Clin Res. 1985;11(6):383-5.

PMID:3939124
Abstract

To assess the rapid bactericidal properties of MT-141, a new cephamycin antibiotic, bacteriological response to MT-141 and latamoxef was compared in complicated urinary tract infections. Although MT-141 was less potent in terms of its MICs than latamoxef against bacterial isolates and was eliminated more slowly than latamoxef from the kidney, MT-141 gave a greater rate of decrease in urinary bacterial counts than latamoxef 6 hours after administration.

摘要

为评估新型头孢霉素抗生素MT-141的快速杀菌特性,在复杂性尿路感染中比较了MT-141和拉氧头孢的细菌学反应。尽管MT-141对细菌分离株的最低抑菌浓度(MIC)比拉氧头孢低,且从肾脏清除比拉氧头孢慢,但给药6小时后,MT-141使尿细菌计数下降的速率比拉氧头孢更大。

相似文献

1
Comparison of rapid bacteriological response to MT-141 and latamoxef in complicated urinary tract infections.MT-141与拉氧头孢治疗复杂性尿路感染的快速细菌学反应比较。
Drugs Exp Clin Res. 1985;11(6):383-5.
2
Effects of MT-141, a new cephamycin antibiotic, on acute urinary tract infections.新型头孢霉素抗生素MT-141对急性尿路感染的影响。
Drugs Exp Clin Res. 1985;11(6):379-82.
3
[Clinical experience with cefmetazole in the urological field].[头孢美唑在泌尿外科领域的临床经验]
Hinyokika Kiyo. 1983 Apr;29(4):459-63.
4
[Cefminox versus cefotaxime in the treatment of complicated urinary tract infection].
Actas Urol Esp. 1995 Sep;19(8):635-41.
5
Clinical experience in the treatment of complicated urinary tract infection with different doses of moxalactam (lamoxactam).
Int J Clin Pharmacol Ther Toxicol. 1983 Apr;21(4):209-12.
6
Clinical studies of moxalactam in complicated urinary tract infections.
Rev Infect Dis. 1982 Nov-Dec;4 Suppl:S692-5. doi: 10.1093/clinids/4.supplement_3.s692.
7
Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.拉氧头孢。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1983 Oct;26(4):279-333. doi: 10.2165/00003495-198326040-00001.
8
Moxalactam therapy for bacterial infections.莫西拉坦治疗细菌感染。
Arch Intern Med. 1981 Nov;141(12):1607-12.
9
[Microbiological, kinetic and clinical study on a new cephamycin: cefotetan].[一种新型头孢霉素:头孢替坦的微生物学、动力学及临床研究]
Minerva Med. 1983 Jun 30;74(27):1639-50.
10
[Clinical evaluation of moxalactam].
Sem Hop. 1983 Jun 30;59(26):1990-3.